Page 29 - Pharmaceutical Firms

Without innovation Indian pharma cannot touch $130 bn by 2030: Industry

Sun Pharma says it eyes $1.5 bn from innovative products in 3-4 years

US-based Amneal Pharmaceuticals acquires Puniska Healthcare for Rs 700 cr

US-based Amneal Pharmaceuticals Inc on Tuesday said it has acquired Ahmedabad-based drug firm Puniska Healthcare Pvt Ltd for a total value of around Rs 700 crore. The acquisition significantly enhances Amneal's injectables manufacturing infrastructure, capabilities, and capacity to support the US market and serve as a foundation for international markets, the company said in a statement. Puniska includes a 293,000 square foot, manufacturing facility in Ahmedabad, with a number of sterile injectable production lines. Production capabilities include robotic, aseptic and lyophilize vial lines, emulsion line, and large-volume parenteral bag line, it added. The acquisition also brings to the company approximately 550 Puniska employees with key capabilities in injectables manufacturing, R&D and commercialisation, Amneal said. "This acquisition is a pivotal step that meaningfully enhances our injectables capabilities for the US market and enables international expansion, including in ...

AstraZeneca Pharma India Q2 net profit declines 55% to Rs 12 crore

The drug firm on Tuesday reported a 54.65 per cent decline in its net profit

Cadila Healthcare Q2 PAT up by 6% YoY to Rs 597 cr, revenue up 3%

The company's EBIDTA margin for the quarter was 22.7 per cent, up by 50 basis points

Drug maker Lupin reports consolidated net loss of Rs 2,098 cr in Q2

Drug maker Lupin on Thursday reported a consolidated net loss

Q2 preview: Non-Covid revenues to hint at normalisation for healthcare cos

Companies may, however, report sequential drop in numbers as Q1FY22 coincided with outbreak of second Covid wave, say brokerages

Lupin launches generic Duexis tablets in US to treat rheumatoid arthritis

Drug firm Lupin on Wednesday said it has launched generic Duexis tablets used to treat the symptoms of rheumatoid arthritis and osteoarthritis in the US market.

Back to old normal: Pharma industry returns to pre-pandemic growth level

In this first instalment of a four-part series on how some of the defining numbers in key sectors are springing back to the pre-pandemic level, Sohini Das looks at India's pharmaceutical sector

Morepen Labs starts production of Russia's Sputnik V Covid-19 vaccine

Pharma major Morepen Laboratories has started the production of the test batch of the Russian Sputnik V coronavirus vaccine in Himachal Pradesh, the company has said

Best of BS Opinion: A jab at veracity, Jet Airways revival, and more

Here are the best of Business Standard's opinion pieces for Thursday

Honeywell launches authentication tech to prevent counterfeit pharma drugs

Honeywell on Monday announced digital authentication technology for the pharmaceutical industry in response to the growing menace of counterfeit products

Indian envoy holds meetings with CEOs of top US companies on Covid crisis

The Indian envoy in the US is having an intense engagement with the CEOs of top American companies to help India get the necessary medical equipment and drugs to combat the pandemic

Venus Remedies posts 61% increase in FY21 annual sales at Rs 548 crore

Pharmaceutical firm Venus Remedies has recorded a 61% increase in annual sales at Rs 548.12 crore in the financial year 2020-21

Seeking clarity, guidance from govt for Covid vaccine import: Cipla

Pharma major Cipla on Tuesday said it is seeking clarity and guidance from the government on the possible roadmap to import vaccine, while stressing that it has been at the forefront of Covid-19 care

Indore-based Modern Lab to manufacture Black Fungus drug Amphotericin B

The Madhya Pradesh government has given permission to the Indore-based Modern Laboratories to manufacture Amphotericin B drug used in the treatment of Black Fungus, White Fungus, and Yellow Fungus

Divi's Labs Q4 net profit jumps 29% at Rs 502 crore on robust sales

Drug firm Divi's Laboratories on Saturday reported a 29.30 percent rise in its consolidated net profit to Rs 502.02 crore for the quarter ended March 31, 2021, on account of robust sales

Zydus introduces scratch code in critical drug packs to fight counterfeit

Drug firm Zydus Cadila on Friday said it has introduced a new feature in the packaging of its critical drugs to help patients ensure that the product is not fake or counterfeited

Drugmaker Zydus Cadila's fourth quarter net profit up 73% at Rs 679 crore

Total income from operations of Rs 3,847 crore was up by 3 per cent from Rs 3,752 crore in Q4 FY20.

Pharma sector's Q4 results show moderate gains amid Covid-19 pandemic

The ongoing April-June quarter should see strong growth due to low base of last year

Covid second wave pushes India's pharma industry growth to 59% in April

The fresh wave of Covid-19 in the country has pushed up sales of medicines and resulted in exponential growth for the pharmaceutical sector